Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 10/20 | 0.43 |
| ▸ | CA2 | P00918 | 10/20 | 0.43 |
| ▸ | CA9 | Q16790 | 9/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA4 | P22748 | 3/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401308 | 0.87 | CA2 (0.47) | CDK2TRPA1ATMCA1CA2 | |
| SCHEMBL31310995 | 0.87 | CA2 (0.47) | CDK2TRPA1ATMCA1CA2 | |
| Hydrochloric Acid SCHEMBL19211699 | 0.85 | CA2 (0.45) | CDK2TRPA1ATMCA1CA2 | |
| Hydrochloric Acid SCHEMBL1017217 | 0.85 | CA2 (0.45) | CDK2TRPA1ATMCA1CA2 | |
| SCHEMBL27560440 | 0.80 | CA2 (0.41) | CDK2TRPA1ATMCA1CA2 | |
| Trifluoroacetic Acid SCHEMBL3610284 | 0.80 | ALDH1A1 (0.42) | CDK2TRPA1ATMCA1CA2 | |
| Benzene SCHEMBL28180960 | 0.77 | CA2 (0.54) | CA1CA2CA9CA12CA4 | |
| SCHEMBL10808580 | 0.77 | CA2 (0.52) | CDK2CA1CA2CA9CA12 | |
| Phenol SCHEMBL27466375 | 0.77 | TDP1 (0.58) | TRPA1ATMCA1CA2CA9 | |
| Hydroquinone SCHEMBL28072711 | 0.77 | ESR1 (0.44) | TRPA1ATMMCL1HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295973-A1 | METHODS AND COMPOSITIONS OF DERIVATIVES OF PROBUCOL FOR THE TREATMENT OF DIABETES | SALUTRIA PHARMACEUTICALS LLC | 2012-11-22 | — | — | US | disclosed |
| US-8252840-B2 | administering monoesters of probucol, such as AGI-1067, succinobucol | SALUTRIA PHARMACEUTICALS LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-20080280979-A1 | Methods and Compositions of Derivatives of Probucol for the Treatment of Diabetes | CRABTREE ACQUISITION CO, LLC | 2008-11-13 | — | — | US | disclosed |
| US-20050196819-A1 | Methods and compositions to lower plasma cholesterol levels | ATHEROGENICS PHARMACEUTICALS, INC. | 2005-09-08 | — | — | US | disclosed |
| US-6887712-B1 | Methods and compositions to lower plasma cholesterol levels | ATHEROGENICS, INC. (US) | 2005-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280979-A1 | Methods and Compositions of Derivatives of Probucol for the Treatment of Diabetes | PNLIP, SLC5A2, LIPC | CDK2 4693/4885TRPA1 3797/4885ATM 3872/4885 |
| US-20120295973-A1 | METHODS AND COMPOSITIONS OF DERIVATIVES OF PROBUCOL FOR THE TREATMENT OF DIABETES | PNLIP, SLC5A2, LIPC | CDK2 4693/4885TRPA1 3797/4885ATM 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.